Advice

In the absence of a submission from the holder of the marketing authorisation

aliskiren (Rasilez) is not recommended for use within NHSScotland for the treatment of essential hypertension.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice41KB (PDF)

Download

Medicine details

Medicine name:
aliskiren (Rasilez)
SMC ID:
462/08
Indication:
for the treatment of essential hypertension
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Cardiovascular system
Submission type
Non submission
Status
Not recommended
Date advice published:
12 May 2008